Peer-review started: April 25, 2018
First decision: May 8, 2018
Revised: June 26, 2018
Accepted: June 28, 2018
Article in press: June 28, 2018
Published online: August 7, 2018
Processing time: 104 Days and 14.4 Hours
To assess the role of narrow band ultraviolet B (UVB) as a treatment option in peritoneal dialysis patients with refractory uremic pruritus.
In this retrospective study, 29 adult patients with end stage renal failure on peritoneal dialysis, and who had refractory uremic pruritus, were given narrow band UVB radiation as an add-on therapy to standard care for a duration of 12 wk. The response to the pruritus was assessed both weekly and at the end of the study period using a visual analogue score (VAS).
The average VAS score at the end of the study was 3.14 ± 1.59, which was significant compared to the baseline value of 7.75 ± 1.02 (P < 0.05). Improvements in symptoms were noted in 19 out of 21 (90.4%) patients. However, relapse occurred in six out of the 19 patients who responded. The dropout rate was high during the study period (33.3%).
Narrow band UVB is effective as an add-on therapy in peritoneal dialysis patients with refractory uremic pruritus. However, the present regime is cumbersome and patient compliance is poor.
Core tip: Uremic pruritus is a very distressing condition commonly seen in patients with advanced renal failure. Patients respond poorly to the currently available treatment regime. Narrow band ultraviolet (NUV-B) radiation is a treatment option in patients with refractory symptoms. In this study, we selected patients on peritoneal dialysis who had refractory pruritic symptoms, and used NUV-B as an add-on therapy to the standard medical care for a period of 12 wk. We found that using NUV-B improved symptoms in more than 90% of patients. However, the present regime used is not patient-friendly and compliance is poor.